hsa-miR-185-3p

ncRNA information

ncRNA name

hsa-miR-185-3p

Specific or universal ncRNAs

Specific ncRNAs

Class

MicroRNA

Biomarker

None

Biomarker application

Upstream regulatory factors

Not available

Downstream target

Not available

Cancer information

Cancer name

Lung Cancer

Cancer site

qRT-PCR,Western blot,Dual-luciferase assay

Treatment information

Treatment type

Chemotherapy

Drug

Erlotinib

Impact of wild-type ncRNA on chemotherapy resistance

Impact of knockdown of ncRNA on chemotherapy resistance

Up

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

These findings revealed a novel mechanism in which downregulation of miR-185-3p may induce overexpression of PFKL and MET and confer ER resistance in lung cells

Tissue resource

normal and tumor tissues of ER-resistant and ER-sensitive lung cancer

human lung cancer cell lines H1299

human lung cancer cell lines A549

Experiment

None


Institute

Nanjing Medical Hospital

Procell

Country

China

China

Continent

Asia

Asia